Orchestra BioMed Holdings (OBIO) Interest Expenses (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Interest Expenses data on file, last reported at $2.7 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 479.87% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 5800.0% increase from a year earlier, with the FY2025 full-year figure at $108.3 million, up 15.29% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.7 million, up from $361000.0 in the prior quarter.
• Over the last five years, Interest Expenses for OBIO reached as high as $8.3 million in Q2 2024 and fell as low as -$579000.0 in Q4 2024.
• Historically, Interest Expenses has averaged $1.7 million across 5 years, with a median of $387000.0 in 2022.
• On a YoY basis, Interest Expenses climbed as much as 1836.69% in 2023 and fell as far as 184.89% in 2023.
• Year by year, Interest Expenses stood at $331000.0 in 2022, then sank by 184.89% to -$281000.0 in 2023, then plunged by 106.05% to -$579000.0 in 2024, then jumped by 162.35% to $361000.0 in 2025, then jumped by 642.11% to $2.7 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $2.7 million in Q1 2026, $361000.0 in Q4 2025, and $225000.0 in Q3 2025.